Neurogene Inc. (NGNE) Cash Flow Statement
Neurogene Inc. (NGNE) generated -$86.8M of operating cash flow over the twelve months to 2026-06-30, spent $890000 on capital expenditure and had free cash flow of -$87.7M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
NGNENeurogene Inc.Follow NGNE — free
—
Price chart with a free account
- Market cap
- 471.3M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 11 Nov, in 18 days
| Line | FY2018 Dec 18 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|
| Operating cash flow | -31.6 | -70.6 | -77.2 | -86.8 | |
| Capital expenditure | 0.0 | 0.8 | 1.2 | -0.9 | |
| Free cash flow | -31.6 | -71.4 | -78.4 | -87.7 | |
| Stock-based compensation | 4.7 | 8.3 | 14.2 | — |
USD millions · SEC XBRL
Neurogene Inc. — questions
- What is Neurogene Inc.'s operating cash flow?
- -$86.8M over the twelve months to 2026-06-30.
- How much does Neurogene Inc. spend on capital expenditure?
- $890000 over the twelve months to 2026-06-30.
- What is Neurogene Inc.'s free cash flow?
- -$87.7M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from Neurogene Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.